4DMedical Shares Close Out Volatile Month Negative, As Resistance Shapes Up

4DMedical shares (ASX:4DX) rounded out a turbulent August with a 6.04% decline in the final trading session, closing at A$3.42 and finishing the month 5.79% lower. The late fade reflects a market caught between genuinely impressive commercial momentum and persistent concerns over cash burn, a stretched valuation and a less forgiving interest-rate environment.

The month’s price action was anything but sideways. 4XDX surged roughly 30% across the first three trading sessions of August before stalling in the A$4.70 region, the same zone that had rejected the stock’s advance in June. That second failure has etched a textbook double top on the chart, transforming A$4.70 from a potential springboard into a well-defined resistance ceiling and inviting technical selling.

The subsequent unwind back into the mid-A$3s, punctuated by the 6.04% final-session drop, is consistent with profit-taking from traders who rode the prior run-up. Macro conditions added fuel to the move into the final session, as hawkish weekend commentary from Kevin Warsh pushed US bond yields higher, a classic headwind for long-duration growth names.

Rising yields increase the discount rate applied to future cash flows, disproportionately pressuring early-stage, loss-making companies whose valuations rest on profits expected years into the future. With positioning already stretched and a failed breakout on the chart, the rates shock likely amplified selling into the month-end close.

What Has Been Driving the 4DX Share Price

Beneath the volatility, 4DMedical’s latest full-year result painted a picture of rapid growth alongside heavy investment. Operating revenue rose approximately 21-23% to around A$7.1-7.2 million, driven by underlying SaaS and scan-based revenue. The adjusted net loss improved modestly, by about 7%, to roughly A$32.9 million, while the statutory net loss ballooned to approximately A$203 million, a figure driven largely by non-cash remeasurement of the Pro Medicus loan and associated derivatives rather than core operating outflows.

Gross margins remained above 90%, highlighting the scalability of the software model, and net tangible assets per share improved to A$0.17 from negative territory a year earlier. The company raised about A$233 million through placements during the year and ended the period with approximately A$278 million in cash, a multi-year runway, though operating cash outflows continue at roughly A$9-10 million per quarter.

Operationally, momentum is real. The CT:VQ platform has moved from early adoption in leading US academic centres into the outpatient market via a three-year commercial agreement with SimonMed Imaging, covering more than 170 imaging centres across 10 states on full commercial terms with no evaluation phase. Globally, 4DMedical now delivers SaaS products across 540 sites excluding SimonMed, up 39% year-on-year, and posted a record 105,970 scans in the fourth quarter. Full-year scan volumes rose 77% to 344,075.

The growth pipeline extends further. The CLEAR program with Massachusetts General Hospital targets a US pulmonary embolism opportunity estimated at around US$3 billion. TGA approval and initial paid contracts have opened the Australian market. A contract with GlaxoSmithKline, alongside ongoing engagement with AstraZeneca, positions the company in respiratory drug development analytics. In Washington, the bipartisan AIRCARE for Vets Act (H.R.9666) proposes a pilot program using 4D functional lung imaging with up to US$20 million in authorised funding.

The company has also been on what observers describe as a deal blitz: a A$3.4 million investment in US firm RevealDx, an agreement to acquire European AI group contextflow for approximately A$18.6 million plus contingent consideration, and US$2 million in funding for the CLEAR program, an ecosystem build-out spanning lung cancer screening, incidental findings and care coordination.

What Lay Ahead?

Technically, the double top at A$4.70 sets a clear target, if sentiment can shift towards a retest, currently a long way off. A decisive break above that zone would invalidate the bearish pattern and could reopen the path to new highs, while sustained weakness below the mid-A$3s would risk a deeper retracement of the prior rally.

Fundamentally, the debate hinges on timing. If scan growth near 77% annually converts into reimbursed, recurring revenue at scale, operating leverage on a 90%-plus gross margin base could be powerful. If conversion lags, a A$10 million quarterly burn against a A$7 million revenue base raises the prospect of further dilution, particularly with acquisition integration now added to the execution list. Further shifts in global rate expectations will likely remain an outsized swing factor either way.

4DMedical exits August as a company with genuine commercial traction and a fortified balance sheet, but also one whose valuation demands proof that momentum can become durable cash flow, leaving the shares hostage to both delivery milestones and the direction of bond yields in the months ahead.